<DOC>
	<DOCNO>NCT00121667</DOCNO>
	<brief_summary>The purpose clinical research study learn whether Saxagliptin add Metformin therapy effective Metformin alone treatment type 2 diabetic subject sufficiently control Metformin alone</brief_summary>
	<brief_title>Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone</brief_title>
	<detailed_description>All subject participate lead-in period , qualify subject continue short-term randomized treatment period . Subjects complete short-term period eligible enter long term extension period . Also , subject short-term period elevate blood sugar require additional medication blood sugar control eligible enter long-term treatment extension period receive pioglitizone add onto blind study medication</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes mellitus require treatment least 1500 mg great 2550 mg maximum tolerate dose Metformin therapy least 8 week prior screen . HbA1c &gt; = 7.0 % &lt; = 10.0 % Body mass index &lt; = 40 kg/m2 Fasting Cpeptide &gt; = 1 ng/dL Symptomatic poorly control diabetes Recent cardiac cerebrovascular event Serum creatinine &gt; = 1.5 mg/dL male &gt; = 1.4 mg/dL female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>